Servier submits a Marketing Authorization Application to the

Servier submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO (ivosidenib tablets) for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma

- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme - TIBSOVO is the first IDH1 mutation specific targeted therapy submitted in Europe - The submission

Related Keywords

Norway , Iceland , Liechtenstein , Paris , France General , France , Prnewswire Servier , Kostenloser Wertpapierhandel , Claude Bertrand , Philippe Gonnard , European Union , European Medicines Agency , Servier Group , Marketing Authorization Application , Executive Vice President Global Medical , Patient Affairs , Servier , Ubmits , Marketing , Authorization , Application , European , Medicines , Agency , Ibsovo , Ivosidenib , Tablets , Patients , Cdh1 , Mutated , Cute , Amyeloid , Leukemia , Cholangiocarcinoma ,